JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses

Johnson & Johnson’s Innovative Medicine revenue rose 7.7% year over year to $16.76 billion in Q3 2026, with operational sales growth of 7.9%, led by Darzalex (+15.4% to $4.24 billion) and Tremfya (+68.3% to $2.40 billion). Stelara sales fell 54.4% to $716 million, reducing segment operational growth by approximately 690 basis points; patent expirations and generic competition are expected to weigh on growth in Q4 and 2027. J&J expects above-market segment growth over time, but consensus 2026 and 2027 EPS estimates have declined to $11.12 and $11.55, respectively, over the past 30 days.

Analysis

The key risk is not the current product cliff in isolation, but the narrowing window for replacement growth: the market has to underwrite launch adoption and continued scaling in newer franchises while legacy erosion persists. That creates an execution-sensitive earnings stream, where modest uptake misses can have an outsized effect on 2027 estimates and the premium multiple. The recent downward estimate revisions despite strong underlying franchise growth suggest the market is already focusing on the bridge, not just headline segment growth.

Near term, Q4 and 2027 guidance are the catalysts; the main swing variables are the pace of Stelara substitution, U.S. Simponi biosimilar entry, and whether newer products contribute enough to offset erosion. Over 6–18 months, successful launches and label expansions could rebuild confidence, but pipeline potential is not equivalent to realized revenue. Competitors such as AbbVie and Amgen may benefit where physicians or payers shift toward alternative immunology treatments, though the extent depends on indication, access, and clinical choice—not simply Stelara loss.

Contrarian view: the diversified portfolio and growth in newer medicines may make the erosion look scarier than the consolidated earnings impact ultimately proves. Conversely, the valuation premium leaves less room for execution slippage; the risk is multiple compression before the long-term pipeline is fully reflected in sales.

Key Decisions for Investors

• Avoid adding to JNJ on franchise-growth headlines; consider trimming an overweight or maintaining a modest relative underweight into the next results and guidance update. The setup is more compelling as a valuation-versus-revision risk than as a claim of structural business deterioration.
• Treat a short-JNJ/long diversified pharma-peer basket as a relative-value watch, not a high-conviction outright short. Reassess after comparing peer valuation, estimate revisions, and business-specific catalysts; the article does not provide enough peer data to size the pair responsibly.
• Track quarterly product-level sales, prescription/share trends, U.S. Simponi biosimilar timing, and launch uptake for newer medicines. These are the missing datapoints needed to test whether replacement growth is genuinely absorbing legacy erosion.
• Falsify the cautious thesis if subsequent results stabilize forward estimates and demonstrate broad-based new-product growth sufficient to offset continued legacy declines. Strengthen it if guidance or consensus estimates are cut again, or if launches underdeliver while erosion accelerates.